Last reviewed · How we verify
NCT03044002: BIO4AMB
BIOTRONIK 4French for AMBulatory Peripheral Intervention
trial testing Biotronik 4 French Portfolio in Peripheral Artery Disease in 821 participants. Completed in 20 October 2020.
20 October 2020
Quick facts
| Lead sponsor | Biotronik AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 821 |
| Start date | 17 March 2017 |
| Primary completion | 20 October 2020 |
| Estimated completion | 20 October 2020 |
| Sites | 5 locations across Belgium, Austria, Switzerland, France |
Drugs / interventions tested
- Biotronik 4 French Portfolio
- 6 French Portfolio
Conditions studied
- Peripheral Artery Disease — all drugs for Peripheral Artery Disease →
- Access Site Complication — all drugs for Access Site Complication →
- Outpatient Treatment — all drugs for Outpatient Treatment →
Sponsor
Biotronik AG
Who can join
Adults 18 to 99, any sex, with Peripheral Artery Disease or Access Site Complication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
BIOTRONIK 4French for AMBulatory peripheral intervention. A multicenter, controlled trial comparing 4French versus 6French femoral access for endovascular treatment of lower-extremity peripheral artery disease in an ambulatory setting: BIO4AMB
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Outcomes of Ambulatory Endovascular Treatment Using 4-French and 6-French Femoral Access Strategies: The Bio4amb Multicentre Trial.
Brodmann M, Deloose K, Steinmetz E, Regnard O, et al · · 2021 · cited 5× · PMID 33367944 · DOI 10.1007/s00270-020-02738-5
Verify or expand the search:
- PubMed search for NCT03044002
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Artery Disease
Currently open trials in the same condition.
- NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
- NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
- NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting
Other Biotronik AG trials
Trials by the same sponsor.
- NCT06758921 — Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Per · recruiting
- NCT05831319 — Evaluation of Standard of Care Practices, Procedural Outcomes and In-hospital Complications of Peripheral Endovascular P · completed
- NCT04830228 — BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions · active not recruiting
- NCT04555174 — BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry · active not recruiting
- NCT04250909 — Retrospective Follow-up of BIOLUX P-I/-II · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03044002 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biotronik AG
- Last refreshed: 1 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03044002.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing